Publications
Publications 12701 - 12725 de 33557
| Titre | DOI |
|---|---|
|
FOLFIRI plus bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9-FFCD 0802) T. Aparicio; B. Linot; K. Le Malicot; O. Bouche; V. Boige; E. Francois; F. Ghiringhelli; J.L. Legoux; M. Ben Abdelghani; J.M. Phelip; R. Faroux; L. Dahan; J. Taieb; L. Bedenne 2015 |
10.1016/j.dld.2015.01.146 |
|
FOLFIRI3-aflibercept as second- or later-line therapy in patients with metastatic colorectal cancer C. Carola; F. Ghiringhelli; S. Kim; T. Andre; J. Barlet; L. Bengrine; H. Marijon; M.Line Garcia; C. Borg; L. Dainese; N. Steuer; A.K. Larsen; A. de Gramont; B. Chibaudel 2018 |
10.1200/JCO.2018.36.4_suppl.817 |
|
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer C. Carola; F. Ghiringhelli; S. Kim; T. Andre; J. Barlet; L. Bengrine-Lefevre; H. Marijon; M.L. Garcia-Larnicol; C. Borg; L. Dainese; N. Steuer; H. Richa; M. Benetkiewicz; A.K. Larsen; A. de Gramont; B. Chibaudel 2018 |
10.5306/wjco.v9.i5.110 |
|
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin J. Hadoux; P. Afchain; T. Walter; D. Tougeron; V. Hautefeuille; C. Monterymard; V. Lorgis; F. Thuillier; E. Baudin; J.Yves Scoazec; C. Lepage; R. Desgrippes 2021 |
10.1016/j.dld.2021.04.016 |
|
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial J.B. Bachet; O. Lucidarme; C.B. Levache; E. Maillard; J.L. Raoul; T. Lecomte; C. Desauw; F. Brocard; S. Pernot; G. Breysacher; J.P. Lagasse; F. Di Fiore; P.L. Etienne; O. Dupuis; A. Aleba; C. Lepage; J. Taieb 2017 |
|
|
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial J.B. Bachet; O. Lucidarme; C.B. Levache; E. Barbier; J.L. Raoul; T. Lecomte; C. Desauw; F. Brocard; S. Pernot; G. Breysacher; J.P. Lagasse; F. Di Fiore; P.L. Etienne; O.J.M. Dupuis; A. Aleba; C. Lepage; J. Taieb; F.F.C.D.1102 Investigators 2018 |
10.1016/j.ejca.2018.09.006 |
|
FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer M. Chaix; J. Vincent; V. Lorgis; F. Ghiringhelli 2014 |
10.1159/000361031 |
|
FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study-Prodige 14-ACCORD 21 (METHEP-2), a unicancer GI trial. M. Ychou; M. Rivoire; S. Thezenas; R. Guimbaud; F. Ghiringhelli; A. Mercier-Blas; L. Mineur; E. Francois; F. Khemissa; D. Moussata; Y. Becouarn; P. Houyau; T. Aparicio; R. Adam; M.P. Galais; F. Audemar; E. Assenat; T. Stanbury; O. Bouche 2016 |
10.1200/JCO.2016.34.15_suppl.3512 |
|
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study. H. Chevalier; A. Vienot; A. Lievre; J. Edeline; F.El Hajbi; C. Peugniez; D. Vernerey; A. Meurisse; P. Hammel; C. Neuzillet; C. Borg; A. Turpin 2020 |
|
|
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study. H. Chevalier; A. Vienot; A. Lievre; J. Edeline; F.El Hajbi; C. Peugniez; D. Vernerey; A. Meurisse; P. Hammel; C. Neuzillet; C. Borg; A. Turpin 2020 |
|
|
FOLFIRINOX De-Escalationin Advanced Pancreatic Cancer: A MulticenterReal-LifeStudy H. Chevalier; A. Vienot; A. Lievre; J. Edeline; F.El Hajbi; C. Peugniez; D. Vernerey; A. Meurisse; P. Hammel; C. Neuzillet; C. Borg; A. Turpin 2020 |
10.1634/theoncologist.2020-0577 |
|
Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy J.F. Guion-Dusserre; A. Bertaut; F. Ghiringhelli; J. Vincent; V. Quipourt; S. Marilier; Z. Tharin; L. Bengrine-Lefevre 2016 |
10.3748/wjg.v22.i42.9378 |
|
FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma: Update of the AGEO cohort E. Auclin; L. Marthey; L. Mas; E. Francois; S. Cunha; J.B. Bachet; D. Tougeron; A. Vienot; T. Lecomte; V. Hautefeuille; J. Forestier; M. Collins; R. Abdallah; R. Coriat; A.L. Pointet; F. Leroy; F. Ksontini; N. Williet; J. Taieb 2019 |
|
|
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer T. Conroy; P. Hammel; M. Hebbar; M. Ben Abdelghani; A.C. Wei; J.L. Raoul; L. Chone; E. Francois; P. Artru; J.J. Biagi; T. Lecomte; E. Assenat; R. Faroux; M. Ychou; J. Volet; A. Sauvanet; G. Breysacher; F. Di Fiore; C. Cripps; P. Kavan; P. Texereau; K. Bouhier-Leporrier; F. Khemissa-Akouz; J.L. Legoux; B. Juzyna; S. Gourgou; C.J. O'Callaghan; C. Jouffroy-Zeller; P. Rat; D. Malka; F. Castan; J.B. Bachet; C.Canc Trial Grp; U.G.I.P.R.O.D.I.G.E. Grp 2018 |
10.1056/NEJMoa1809775 |
|
FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial. E. Lopez-Crapez; A. Adenis; S. Thezenas; E. Assenat; E. Francois; R. Guimbaud; M. Chauvenet; F. Khemissa; F. Audemar; E. Suc; M. Rivoire; F. Ghiringhelli; A. Mercier-Blas; L. Mineur; Y. Becouarn; P. Houyau; T. Stanbury; C. Jouffroy-Zeller; O. Bouche; M. Ychou 2018 |
10.1200/JCO.2018.36.15_suppl.3548 |
|
Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study N. Williet; A. Saint; A.L. Pointet; D. Tougeron; S. Pernot; A. Pozet; D. Bechade; I. Trouilloud; N. Lourenco; V. Hautefeuille; C. Locher; J. Desrame; P. Artru; A.Thirot Bidault; B. Le Roy; D. Pezet; J.M. Phelip; J. Taieb 2019 |
10.1177/1756284819878660 |
|
FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA) D. Malka; F. Castan; E. Francois; O. Bouche; J. Bennouna; F. Ghiringhelli; C. de la Fouchardiere; C. Borg; E. Samalin; J.Baptiste Bachet; J.L. Raoul; F. Cvitkovic; L. Miglianico; L. Bengrine-Lefevre; L. Dahan; C. Lecaille; T. Aparicio; H. Perrier; S. Gourgou; J. Taieb; AGEO 2015 |
10.1200/jco.2015.33.15_suppl.4013 |
|
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial D. Malka; E. Francois; F. Penault-Llorca; F. Castan; O. Bouche; J. Bennouna; F. Ghiringhelli; C. de la Fouchardiere; C. Borg; E. Samalin; J.B. Bachet; J.L. Raoul; L. Miglianico; L. Bengrine-Lefevre; L. Dahan; C. Lecaille; T. Aparicio; T. Stanbury; H. Perrier; A. Cayre; P. Laurent-Puig; S. Gourgou; J.F. Emile; J. Taieb 2019 |
10.1016/j.ejca.2019.04.020 |
|
Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial) S. Pernot; P. Artru; D. Tougeron; C. Monterymard; D. Smith; C. de la Fouchardiere; J.L. Raoul; L. Dahan; R. Guimbaud; P. Michel; J.L. Jouve; O. Pellerin; J. Taieb 2018 |
|
|
Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial) S. Pernot; P. Artru; D. Tougeron; C. Monterymard; D. Smith; C. de la Fouchardiere; J.L. Raoul; L. Dahan; R. Guimbaud; P. Michel; J.L. Jouve; O. Pellerin; J. Taieb 2018 |
|
|
Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial) S. Pernot; P. Artru; D. Tougeron; C. Monterymard; D. Smith; C. de la Fouchardiere; J.L. Raoul; L. Dahan; R. Guimbaud; P. Michel; J.L. Jouve; O. Pellerin; J. Taieb 2018 |
|
|
Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial) S. Pernot; P. Artru; D. Tougeron; C. Monterymard; D. Smith; C. de la Fouchardiere; J.L. Raoul; L. Dahan; R. Guimbaud; P. Michel; J.L. Jouve; O. Pellerin; J. Taieb 2018 |
|
|
FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study A. Zaanan; I. Trouilloud; T. Markoutsaki; M. Gauthier; A.C. Dupont-Gossart; T. Lecomte; T. Aparicio; P. Artru; A. Thirot-Bidault; F. Joubert; D. Fanica; J. Taieb 2014 |
10.1186/1471-2407-14-441 |
|
FOLFOX-aflibercept followed by maintenance therapy with fluoropyrimidine-aflibercept as first-line therapy in patients with metastatic colorectal cancer: A GERCOR single-arm phase II study (VELVET) B. Chibaudel; T. Andre; J.Baptiste Bachet; D. Auby; J. Desrame; G. Deplanque; C. Lecaille; C. Louvet; C. Tournigand; V. Lebrun-Ly; J. Dauba; G. Lledo; M.Line Garcia; N.Baba Hamed; M. Wagner; M. Attia; A. Meurisse; A. Tijeras-Raballand; F. Bonnetain; A. de Gramont; GERCOR 2015 |
10.1200/jco.2015.33.15_suppl.3567 |
|
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized M. Hebbar; B. Chibaudel; T. Andre; L. Mineur; D. Smith; C. Louvet; J.L. Dutel; M. Ychou; J.L. Legoux; M. Mabro; R. Faroux; D. Auby; D. Brusquant; A. Khalil; S. Truant; A. Hadengue; C. Dalban; B. Gayet; F. Paye; F.R. Pruvot; F. Bonnetain; J. Taieb; P. Brucker; B. Landi; M. Flesch; E. Carola; P. Martin; E. Vaillant; A. de Gramont; G.Cooperateu Multidisciplinaire 2015 |
10.1093/annonc/mdu539 |